RHOA and T-cell non-Hodgkin lymphoma: Furthermore, the authors identified 8.2 % of VAV1 mutations in 85 RHOA mutation-negative T-Cell lymphoma samples, and the resulting acceleration of mutated VAV1 protein phosphorylation and subsequent accelerated TCR signaling could also be suppressed by dasatinib [77].